PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones – “PTC518 is the leading oral disease-modifying therapy in development for Huntington’s disease and the economics ...
BIPAVE-001 is a Phase 1/2 trial designed to evaluate the safety, pharmacokinetic, and efficacy of AI-081. The Part A portion is a first-in-human dose escalation study that will determine the ...
Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over ...
BENGALURU, Karnataka, India I 01, 2024 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE ...
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...
SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.
DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...
HAYWARD, CA, USA I1, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first ...
– Interim results indicate cognitive improvement in the active treatment group compared to placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback